Safety and Effectiveness of Hydroxychloroquine and Azithromycin Combination Therapy for Treatment of Hospitalized Patients with COVID-19: A Propensity-Matched Study
ConclusionIn this propensity-matched study, there was no difference in in-hospital mortality, life-threatening arrhythmias, or incidence of PEA arrest between the HCQ-AZM and untreated control groups. QTc intervals were longer in patients receiving HCQ-AZM, but only one patient developed drug-related ventricular tachycardia.
Source: Cardiology and Therapy - Category: Cardiology Source Type: research
More News: Arrhythmia | Azithromycin | Cardiology | Cardiovascular | COVID-19 | Heart | Hydroxychloroquine | Respiratory Medicine | SARS | Study | Ventricular Tachycardia | Zithromax